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Recent studies have demonstrated that MyoD initi-
ates a feed-forward regulation of skeletal muscle
gene expression, predicting that MyoD binds directly
to many genes expressed during differentiation.
We have used chromatin immunoprecipitation and
high-throughput sequencing to identify genome-
wide binding of MyoD in several skeletal muscle cell
types. As anticipated, MyoD preferentially binds to
a VCASCTG sequence that resembles the in vitro-
selected site for a MyoD:E-protein heterodimer, and
MyoD binding increases during differentiation at
many of the regulatory regions of genes expressed
in skeletal muscle. Unanticipated findings were that
MyoDwas constitutively bound to thousands of addi-
tional sites in bothmyoblasts andmyotubes, and that
the genome-wide binding of MyoD was associated
with regional histone acetylation. Therefore, in addi-
tion to regulating muscle gene expression, MyoD
bindsgenomewideandhas the ability tobroadly alter
the epigenome in myoblasts and myotubes.
INTRODUCTION
Skeletal muscle differentiation is regulated by the myogenic
basic-helix-loop-helix (bHLH) transcription factors (Berkes and
Tapscott, 2005; Tapscott, 2005). MyoD and Myf5 are expressed
at the time of myogenic specification and, together with Myoge-
nin (Myog) and MRF4, regulate the expression of skeletal
muscle genes. These myogenic bHLH transcription factors are
expressed almost exclusively in the skeletal muscle lineage,
form heterodimers with members of the E-protein bHLH sub-
family (E2A, E2-2, and HEB), and bind to a consensus E-box
sequence (CANNTG). E-boxes are present in many of the regula-
tory regions of genes expressed in skeletal muscle. However,662 Developmental Cell 18, 662–674, April 20, 2010 ª2010 Elsevier Iwith over fourteen million consensus E-boxes in the genome, it
is likely that every gene has the potential to be bound by MyoD
or other myogenic bHLH factors.
Several mechanisms have been identified that increase the
specificity of binding and activity among bHLH factors. First,
degenerate selection strategies demonstrated that binding
preference is conferred by the internal and flanking nucleotides
in the CANNTG E-box. For example, the MyoD:E-protein heter-
odimer was shown to favor a consensus VCASCTGT site (IUPAC
nomenclature [http://www.iupac.org], where V represents not T,
and S represents G or C), with E-proteins selecting the VCAS,
and MyoD selecting the CTGT (Blackwell and Weintraub,
1990). A similar study with a functional selection strategy, rather
than only binding affinity, identified a slightly different set of core
E-box sequences for MyoD activity: CASKTG (Huang et al.,
1996), where K represents T or G. Second, sequence-function
studies clearly demonstrated that binding affinity did not
always correlate with transcriptional activation, as some E-box
sequences were equivalently bound by MyoD and E-proteins,
but showed different abilities to function as MyoD-responsive
enhancers (Davis et al., 1990; Weintraub et al., 1991). Third, we
have demonstrated that MyoD functions together with other
transcription factors in a feed-forward circuit and often binds
to an E-box site prior to transcriptional activation, which is deter-
mined by the recruitment of cofactors at the specific promoter
(Bergstrom et al., 2002; Penn et al., 2004; Rampalli et al.,
2007). Together, these studies indicate that MyoD-binding
affinity is sensitive to core and flanking E-box sequences, and
that MyoD transcriptional activity can be regulated indepen-
dently of binding affinity. Therefore, it is possible that MyoD
might bind at sites in the genome without regulating regional
gene transcription; however, it is not known how frequently this
might occur, nor whether it might have any other biological
activity.
In this study, we have used chromatin immunoprecipitation
and high-throughput sequencing (ChIP-seq) to identify genome-
wide binding of MyoD in several skeletal muscle cell types.
As anticipated, MyoD binds to many of the genes transcription-
ally regulated during skeletal muscle differentiation. However,nc.
Table 1. Gene Context Analysis of Myod-Binding Sites
Number of Peaksa Number of Genesb Number of Peaks/kbc
Myotube Myoblast Myotube Myoblast Myotube Myoblast
Promoterd 4772 4982 4256 4502 0.153 0.160
Promoter proximale 6349 6417 5085 5313 0.055 0.056
30 f 694 517 579 433 0.022 0.017
Exon 2031 1615 1554 1283 0.032 0.026
Intron 8780 7239 5443 4957 0.011 0.010
Upstreamg 3739 3124 2600 2272 0.015 0.012
Downstreamh 3985 3237 2901 2447 0.015 0.013
Intergenici 6254 5776 0 0 0.005 0.004
Total 25956 23271
aNumber of Peaks: the number of peaks in each category.
bNumber of Genes: the number of genes that peaks are associated with in each category, measured by unique Entrez IDs. If one or more peaks are
located in multiple alternative splice variants of one gene, only one gene is counted.
cNumber of Peaks/kb: number of peaks divided by the total size of the corresponding genomic region in kilobases.
d Promoter: ±500 bp from the transcription start site (TSS).
e Promoter proximal: ±2 kb from the TSS.
f 30 end: ±500 nt from the end of the transcript.
gUpstream: 2 kb to 10 kb upstream of the TSS.
hDownstream: +2 kb to +10 kb from the end of the transcript.
i Intergenic: >10 kb from any annotated gene.
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MyoD Binds Genome WideMyoD also binds to thousands of additional sites genome wide
and induces regional histone acetylation. Therefore, in addition
to regulating the expression of skeletal muscle genes, MyoD
has the potential to broadly alter the epigenome in myoblasts
and myotubes.
RESULTS
Identification of MyoD-Binding Sites
Mouse C2C12 cells (Blau et al., 1983; Richler and Yaffe, 1970;
Yaffe, 1968) are the most widely used cell line to study muscle
differentiation. When maintained in a mitogen-rich culture
medium (e.g., 10%–20% FBS), C2C12 cells grow as myoblasts,
expressing MyoD RNA and protein, but not activating down-
stream genes associated with muscle differentiation. When
cultured in low-mitogen conditions, C2C12 cells differentiate
into skeletal muscle cells and activate the expression of muscle
genes. To identify MyoD-binding sites in muscle cells, we per-
formed MyoD ChIPs in C2C12 cells differentiated into myotubes
for 48 hr. We used three different polyclonal rabbit antisera
raised against different but overlapping fragments of the MyoD
protein (Tapscott et al., 1988), all of which specifically immuno-
precipitated MyoD and not the other myogenic bHLH factors
(see Figure S1A available online). As controls for background
enrichment, we also performed ChIPs with preimmune serum
in C2C12 cells and with the MyoD antisera in mouse embryonic
fibroblasts (MEFs) that do not express MyoD.
Precipitated DNA fragments, ranging from 100 to 300 nucleo-
tides (nt), were subjected to high-throughput sequencing-by-
synthesis on an Illumina Genome Analyzer System that yielded
reads of 35–54 nt from a single end. To identify MyoD-binding
sites, reads with a unique match in the mouse genome were
extended to a total length of 200 nt (the estimated average frag-
ment size), and the number of overlapping reads at each positionDevein the genomewas computed to generate peak heights for MyoD
or the control ChIP samples (see Experimental Procedures).
Reads mapping to the X and Y chromosome were excluded
from our analysis. The three individual antisera were highly
concordant with Pearson correlation coefficients of 0.92, 0.92,
and 0.94 (Figure S1B), and we pooled the data from the
three antisera for further analysis. The small number of regions
enriched in the preimmune immunoprecipitation control was
subtracted from the analysis. A sampling analysis based on the
accumulation of foreground signal indicated that we had suffi-
cient read coverage for each condition (Figure S1C).
Regions Bound by MyoD in C2C12 Myotubes
To choose a reasonable peak height, or coverage, cutoff for
determining MyoD-bound sites in myotubes, we estimated the
false discovery rate (FDR) at various cutoffs. The FDR was
0.018 at a peak-height cutoff of 6 reads, and 107 at a cutoff of
12 reads (Figure S1D). A total of 59,267 and 25,956 peaks were
identified at cutoffs 6 and 12, respectively, and gene-specific
qPCR on 20 sites validated binding (Table S1A). At a similar strin-
gency, an FDR of 106, the controls (preimmune sera, beads
alone, or MyoD antisera in MEFs) had fewer than 200 peaks
(Table S1B). An examination of 9 previously characterized
MyoD-binding sites showed coverage ranging from 16 to 275
reads (Table S1C). Except where noted, for subsequent analyses
we will use the 12-read cutoff as the criteria for a MyoD-binding
region, which remains a very conservative threshold for all cell
types and experimental conditions reported here.
The 25,956 MyoD-binding sites in myotubes identified by a
12-read cutoff are widely distributed both upstream and down-
stream of gene transcription start sites (TSSs) with a high density
near a TSS, but the majority are located more than 10 kb from
a TSS (Table 1; Figure S1E). Approximately 41% of all annotated
genes (7,758 out of 18,054) are bound by MyoD in C2C12lopmental Cell 18, 662–674, April 20, 2010 ª2010 Elsevier Inc. 663
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MyoD Binds Genome Widemyotubes, using a ‘‘gene’’ definition as the region encompassed
by 2 kb from the TSS to +2 kb from the polyadenylation site.
Because many enhancers are more than 2 kb from their regu-
lated TSSs, we assigned MyoD peaks to the closest TSS within
the domain bounded by the insulator factor CTCF, a strategy
previously suggested as reasonable because CTCF is thought
to establish domains within which enhancers and promoters
can interact (Heintzman and Ren, 2009). Because CTCF binding
is largely invariant across different cell types (Heintzman et al.,
2009), we superimposed the CTCF-binding profile previously
determined in mouse embryonic stem cells (SRX 000540, from
the NCBI Sequence Read Archive) with our MyoD ChIP-seq
data and assigned each peak to the closest promoter within
the domain defined by flanking CTCF binding. Of the 35,440
annotated promoters (some of which represent alternative
TSSs of the same gene), 19,823 (56%) have a MyoD peak within
the domain flanked by bound CTCF, and 13,764 (74%) of the
total 18,054 annotated genes have MyoD bound within the
domain flanked by CTCF at one of the TSSs.
Sequence Characteristics in Regions Bound by MyoD
in C2C12 Myotubes
To understand the sequence determinants of MyoD binding in
myotubes, we first examined E-box sequences in the 200 nt
region centered at the MyoD peak summit. A total of 96% of all
peaks contain at least one canonical E-box (CANNTG), with
an average of 2.4 E-boxes per peak, relative to 1.14 in com-
parable control regions (see Experimental Procedures), and
72% of peaks have an E-box within 20 nt of the peak summit.
A strong sequence preference was observed for the E-box
sequences in peak regions (Figure 1A): 74% of peaks have
the CAGCTG E-box (enriched 11-fold); 32% have CACCTG
(enriched 2.5-fold); and 89% have either or both of these two
E-box motifs. Similarly, determining the number of reads that
cover each E-box in the genome identifies CAGCTG and
CACCTG as preferred binding sites, with higher peaks favoring
CAGCTG (Figure S2A).
The two 50 nucleotides flanking the E-box are enriched
for A and G (positions 2 and 3 in Figure 1B), and the 30 flanking
nucleotide is depleted for A (position 10); however, this sym-
metry might reflect the lack of orientation of the core E-box
sequence. If the first 50 flanking nucleotide is fixed, an asymmetry
of E-box flanking sequences in MyoD-bound regions becomes
more apparent (Figure S2B), and the enriched sequences
reflect the nucleotide preference of MyoD:E-protein hetero-
dimers previously identified by in vitro binding selection assays
(Blackwell andWeintraub, 1990). For example, the in vitro-deter-
mined MyoD:E47 and MyoD:E12 heterodimer protein-binding
sequences were NACAGGTGBN and RACAGGTGBH (using
IUPAC nomenclature, where R = A/G, B = not A, H = not G,
and N = any nucleotide), and the consensus flanking binding
sequence of the CAGGTG E-box in our ChIP-seq study is
RRCAGGTGBN (Figure 1B, right panel).
We also performed a de novo motif search on the E-box con-
taining MyoD peaks by using a regression-based method. The
regions under MyoD peaks had a significantly higher GC content
compared to control regions (56% in MyoD peaks versus 44% in
control regions), and we therefore adjusted for GC content with
a regression term (see Experimental Procedures). We started664 Developmental Cell 18, 662–674, April 20, 2010 ª2010 Elsevier Iwith a seed pattern of 6 nt, then iteratively expanded the motif
to a total length of up to 12 nt. The identified motifs are listed
in Figure 1C and in order of enrichment represent: E-boxes
(CASCTG); AP1/c-Fos site (TGAGTCA); Meis site (CTGYCA);
partial match to Runx site (RCCACAG); and two additional
E-boxes (CAGWTG). AP1/c-Fos and Meis have both been impli-
cated in the regulation of myogenic differentiation. Members
of the Runx family of transcription factors have been well
documented to be associated with leukemia, whereas their
role in myogenesis is largely unknown. Without controlling for
GC content during the motif search, the top non-E-box motifs
are composed entirely of C and G bases. The most significant
of thesemotifs, CCGCCC,matches theSp1-binding site, a factor
that has been shown to regulate muscle gene expression with
MyoD.
A small percentage of MyoD-bound regions (4%) do not con-
tain any consensus E-box. Interestingly, most of these regions
are located within 500 nt of a TSS (59%) or overlap with a CpG
island (67%), and have very high GC content (67% average GC
content). Compared to control regions without E-boxes and
within CpG islands, the top motifs were noncanonical E-boxes
CAGSCG and the Sp1 site CCGCCC (Figure 1D).
To complement the motif search, we identified the conserved
TRANSFAC-binding sites in the MyoD-bound regions. Consis-
tent with our motif search findings, the TRANSFAC search
showed significant enrichment for E-box motifs (MyoD, AP-4,
E47, Lmo2, ITF-2, USF2), AP-1-like motifs (FosB), and Sp1 sites
in MyoD-bound regions (Table S2).
MyoD Binding in Myoblasts Compared to Myotubes
Next, we determined MyoD binding in myoblasts at 50% conflu-
ence (log-phase growth) and 95% confluence (prior to transition
to low-mitogen differentiation medium). The location and height
ofMyoD binding in C2C12 cells at 50%and 95%confluencewas
highly concordant, with a Pearson correlation coefficient of 0.85
(Figure 2A). In addition, the majority of sites bound by MyoD in
differentiated myotubes were bound nearly equivalently in
myoblasts (95% confluent), with a Pearson correlation coeffi-
cient of 0.77 (Figure 2B). For example, MyoD binds to regulatory
regions of the Desmin gene (Figure 2C) and the core enhancer of
the MyoD gene (Figure 2D) in both myoblasts and myotubes. In
contrast to the majority of binding sites that do not substantially
change between myoblasts and myotubes, it is striking that
many of the previously identified functional MyoD-binding sites
associated with genes activated during differentiation showed
enhanced MyoD binding in myotubes. For example, at the
Myog promoter (Figure 2E) and the CKM regulatory regions
(Figure 2F), MyoD binding increases substantially in the differen-
tiated myotubes. In summary, the majority of MyoD-binding
regions are bound by MyoD in both myoblasts and myotubes,
and some of these regions are associated with genes expressed
in both myoblasts and myotubes, such as Desmin and MyoD,
whereas a sampling of regulatory regions in genes induced
during differentiation show enhanced MyoD binding in differenti-
ated myotubes compared to myoblasts.
To determine whether differentiation-enhanced MyoD bind-
ing was associated with genes induced during differentiation,
we determined differentially bound peaks between 95% con-
fluent myoblasts and myotubes by using a regression-basednc.
Figure 1. MyoD Binding in C2C12 Myotubes
(A) Average number of each E-box sequence under myotube peaks and control regions, where 1.0 indicates that each peak has, on average, one E-box of that
sequence. Reverse complement sequences were combined. Compared to the controls, myotubes are enriched for CAGCTG and CAGGTG/CACCTG.
(B) Myotube peaks are enriched for 50 A/G and depleted for 30 A at the positions immediately flanking the E-box (CAG[C/G]TG). The size of each nucleotide at
a given position is proportional to the frequency of the nucleotide at that position. The darkness of the line connecting the two adjacent nucleotides is determined
by the corresponding dinucleotide frequency. The counts of patterns on both strands are indicated above the graphs.
(C) Motifs enriched in E-box-containing Myod-binding regions in C2C12 myotube peaks.
(D) Motifs enriched in non-E-box-containing MyoD-binding regions in C2C12 myotube peaks.
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MyoD Binds Genome Wideanalysis. Briefly, we combined the data from the myotubes and
myoblasts and detected 49,472 peaks using a 12-coverage
cutoff, of which 3,926 and 2,169 were identified as myotube-
increased (significantly increased binding in myotubes) and
myotube-decreased (significantly decreased binding in myo-Devetubes) peaks, respectively, by using a statistical criterion (see
Experimental Procedures). The remaining 43,377peaks are cate-
gorized as unchanged. Differentially bound peaks were assigned
to a gene based on the closest TSS within the region flanked by
CTCF-binding sites. A total of 3124 myotube-increased peakslopmental Cell 18, 662–674, April 20, 2010 ª2010 Elsevier Inc. 665
Figure 2. MyoD Binding in C2C12
Myoblasts Compared to C2C12 Myotubes
(A) 50% and 95% confluent C2C12 myoblasts
share similar binding profiles. The x and y axes
of the scatter plot correspond to the Variance
Stabilization and Normalization (vsn)-transformed
number of reads in 50% and 95% confluent
C2C12 myoblasts in the combined peak regions.
The middle diagonal line is the linear fit. The two
flanking lines define the 95% confidence interval
for differential peaks. Gray scale values represent
a smoothed density estimate for the bulk of the
data. Individual points shown at the fringes repre-
sent the outliers in low-density regions. Peaks
within ±2 kb of the TSS of selected muscle
genes (Myh3, Acta, Myog, Cdh14, Mef2a, Des,
and Ckm) are annotated by gene names. Note
that some genes have multiple peaks within the
promoter regions.
(B) 95% C2C12 myoblasts and C2C12 myotubes
have overlapping but different binding profiles.
The scatter plot is similar to that in (A).
(C) MyoD-binding profile at the Desmin locus. The
y axis scale was adjusted by the total number of
reads in each cell type, so that nondifferentially
bound peaks appear roughly the same heights in
all three tracks. The two peaks match the two
previously characterized MyoD-binding sites
(Tam et al., 2006).
(D) The MyoD-binding profile at the MyoD locus
identifies three previously characterized MyoD-
binding sites (stars) (Asakura et al., 1995; Gold-
hamer et al., 1992; Tapscott et al., 1992) and
several new MyoD-binding sites.
(E) The MyoD-binding profile at the Myog locus
identifies the known MyoD-binding site in the
promoter region, as well as a new binding site at
the 30 end of the gene.
(F) The MyoD-binding profile at the Ckm locus
identifies all known MyoD-binding sites.
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MyoD Binds Genome Widewere assigned to 1588 genes, and 1723 myotube-decreased
peaks were assigned to 950 genes. Of these, 105 genes were
assigned both myotube-increased and myotube-decreased
peaks.
Geneset enrichment analysis (GSEA) showed that genes asso-
ciated with myotube-increased peaks are enriched for Gene
Ontology (GO) categories related to muscle formation and func-
tion, whereas genes associated with myotube-decreased peaks
are enriched for GO terms related to cell proliferation and cell
communication (Table 2). A similar GSEA analysis showed signif-
icant enrichment in cell mobility and cell adhesion GO categories
for genes associated with peaks that decrease as cells reach
confluence, whereas no informative GO categories are enriched
for genes associatedwith peaks that increase as cells reach 95%
confluence (Table S3A).
To determine whether motifs for specific transcription factors
are associated with peaks that increase or decrease duringmyo-
tube differentiation, we carried out a de novo motif search
comparing myotube-increased peaks or myotube-decreased
peaks to unchanged peaks. The myotube-increased peaks
are enriched for E-boxes, MEF2-like sites (AAATAG), and Meis-
like sites (CTGCCA), and depleted for AP1/fos-like motifs666 Developmental Cell 18, 662–674, April 20, 2010 ª2010 Elsevier I(TGAGTCA) and Sp1-like consensus (CCGCCC) (Figure 3A).
The myotube-decreased peaks are enriched for AP1/fos-like
motifs and RP58-like motifs (ACATCTG) (Figure 3B). Similar
results were obtained by using the conserved TRANSFAC-
binding sites (Table S3B).
AP1 has been shown to regulate muscle differentiation
(Andreucci et al., 2002; Aoki et al., 1998), and RP58 expression
is activated by MyoD and suppresses expression of Id2 and
Id3 (Yokoyama et al., 2009). It is interesting to note that the
RP58-binding sites that repress Id2 and Id3 overlap with the
E-boxes in MyoD peaks that decrease with differentiation at
these genes (Figures 3C and 3D), suggesting that the MyoD
induction of RP58 feeds forward to repress MyoD binding.
Comparing our ChIP-seq data to a previous MyoD ChIP-
on-chip study that identified 126 genes bound by MyoD in
C2C12 myoblasts and/or myotubes (Blais et al., 2005), almost
all of the MyoD-bound promoters they identified have MyoD
peaks in our ChiP-seq study, their myotube-bound promoters
tend to have peaks that increase with differentiation, and
their myoblast-bound promoters tend to have peaks that
decrease with differentiation (Figure S3A), indicating reasonable
agreement.nc.
Table 2. Gene Ontology Analysis on Differentially Bound Peaks in Myoblasts versus Myotubes
GO Categories Enriched in Genes Associated with Myotube-Increased Peaks
GOID Term P Value ORa Countb Sizec Ontd
GO:0005856 cytoskeleton 2.05E-11 2.40 94 490 CC
GO:0043292 contractile fiber 6.98E-09 5.85 22 58 CC
GO:0030016 myofibril 1.96E-08 5.74 21 56 CC
GO:0044449 contractile fiber part 2.58E-08 5.97 20 52 CC
GO:0030017 sarcomere 4.95E-08 6.04 19 49 CC
GO:0008092 cytoskeletal protein binding 3.69E-07 2.52 47 227 MF
GO:0007519 skeletal muscle development 2.50E-06 4.13 20 65 BP
GO:0015629 actin cytoskeleton 4.73E-06 3.08 27 111 CC
GO:0003779 actin binding 7.52E-06 2.59 34 159 MF
GO:0006936 muscle contraction 1.93E-05 4.22 16 51 BP
GO:0044430 cytoskeletal part 2.23E-05 2.03 51 294 CC
GO:0031674 I band 2.27E-05 5.67 12 32 CC
GO:0003012 muscle system process 2.54E-05 4.11 16 52 BP
GO:0030029 actin filament-based process 2.89E-05 2.73 27 119 BP
GO:0007517 muscle development 5.06E-05 2.69 26 116 BP
GO Categories Enriched in Genes Associated with Myotube-Decreased Peaks
GO:0044421 extracellular region part 4.59E-09 3.43 37 229 CC
GO:0005576 extracellular region 1.88E-08 2.54 56 457 CC
GO:0007167 enzyme linked receptor protein signaling pathway 7.88E-07 3.17 29 188 BP
GO:0005615 extracellular space 1.70E-06 3.83 21 116 CC
GO:0005125 cytokine activity 5.92E-06 6.08 12 45 MF
GO:0007178 transmembrane receptor protein ser/thr kinase signaling pathway 6.24E-06 5.05 14 61 BP
GO:0007166 cell surface receptor linked signal transduction 8.13E-06 2.09 53 504 BP
GO:0007179 transforming growth factor b receptor signaling pathway 1.18E-05 5.11 13 56 BP
GO:0005102 receptor binding 2.31E-05 2.64 28 209 MF
GO:0008284 positive regulation of cell proliferation 3.46E-05 3.56 17 98 BP
GO:0042127 regulation of cell proliferation 9.33E-05 2.50 26 204 BP
A differentially bound peak was associated to the closest gene measured by distance to TSS within CTCF flanking domains. Analysis is performed
based on unique Entrez ID.
aOR: the odds ratio between the predicted and observed number of genes within the given GO category.
bCount: the number of genes included in the differentially bound peaks.
c Size: the total number of genes for the given functional group.
dOnt: the Geneontology. BP stands for ‘‘biological process,’’ MF stands for ‘‘molecular function,’’ and CC stands for ‘‘cellular component.’’
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MyoD Binds Genome WideAssociation between Differential Binding
and Gene Expression
To evaluate the association between regions showing differential
binding with gene expression, we used Illumina Mouse WG-6
Expression Bead Arrays to measure mRNA abundance in
50% confluent, 95% confluent, and differentiated C2C12 cells.
Among the 45281 features represented on the array, 438 (0.96%)
are differentially expressed between 50% and 95% C2C12
myoblasts, and 1956 (4.3%) are differentially expressed between
95%confluent C2C12myoblasts andmyotubes (FDR < 0.05 and
a two-fold difference). GSEA showed that genes upregulated in
myotubes compared to 95% confluent myoblasts are enriched
for muscle development and cytoskeleton GO categories,
whereas genes downregulated in myotubes are enriched for
cell cycle and cell division-related GO categories (Table S4).
Upregulated genes were significantly associated with a peak
that increased with differentiation (64% of peaks associated
with upregulated genes showed increased binding [p = 1082]),Deveand 63% of peaks associated with downregulated genes
decreased with differentiation (p = 1019) (Figure 3E). In contrast,
GSEA did not show significant enrichment in any GO categories
when comparing 50% and 95% confluent myoblasts, and there
was no clear correlation between expression and differential
binding (Figure 3F).
Although upregulated genes were significantly associated
with peaks that increased with differentiation, absolute peak
height was not a good predictor of sites associated with genes
regulated by MyoD. One method by which to determine the
accuracy of peak height as a discriminator of function is to calcu-
late the Area Under a Receiver Operating Characteristic curve
(AUROC). Comparing peak heights within 2 kb of upregulated
promoters to nonregulated promoters of expressed or nonex-
pressed genes yielded AUROC values of 0.64 and 0.66, respec-
tively (Figures S3B and S3C), where 0.50 would represent no
discriminatory power. For example, a height threshold of 30
would identify 56% of regulated promoters and 33%–30% oflopmental Cell 18, 662–674, April 20, 2010 ª2010 Elsevier Inc. 667
Figure 3. Characteristics of Differentially
Bound Regions between C2C12 Myoblasts
and Myotubes
(A) Motifs enriched (upward arrow) and depleted
(downward arrow) in peaks that increase in
C2C12 myotubes compared to myoblasts.
(B) Motifs enriched in peaks that decrease in
C2C12 myotubes compared to myoblasts.
(C and D) MyoD-binding profiles at the Id2 and Id3
loci showed decreased binding of MyoD after
differentiation. The characterized RP58-binding
sites (Yokoyama et al., 2009) are indicated by
vertical bars.
(E) Differentially bound peaks positively correlate
with differentially expressed genes in 95% C2C12
myoblasts versus myotubes. The x and y axes
correspond to the vsn-transformed number of
reads in 95% confluent C2C12 myoblasts and
myotubes in the combined peaks. Downregulated
and upregulated genes are plotted in the left and
right panels, respectively. Note that in the left
panel, data points are concentrated below the
diagonal line, indicating that genes downregulated
in myotubes have a lower binding affinity in myo-
tubes. In contrast, data points are concentrated
above the diagonal line in the right panel, indi-
cating that genes upregulated in myotubes have
stronger binding in myotubes.
(F) Differentially bound peaks do not correlate with
differentially expressed genes in 50% versus 95%
C2C12 myoblasts. Only the peaks associated
with differentially expressed genes are plotted.
The x and y axes correspond to the vsn-trans-
formed number of reads in 50% and 95%
myoblasts in the combined peaks. Downregulated
and upregulated genes are plotted in the left and
right panels, respectively. Note that the points are
relatively symmetrically distributed around the
diagonal line, indicating that there is no correlation
between the binding affinity and themRNAexpres-
sion levels.
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MyoD Binds Genome Widenonregulated promoters. The discriminatory power of peak
height to predict local promoter regulation increased slightly
when we assessed peaks within the domain flanked by CTCF
binding, with AUROC values of 0.7 and 0.73 comparing regu-
lated promoters to nonregulated expressed and nonexpressed
promoters, respectively (Figures S3D–S3F), and was 0.77
compared to intergenic domains bounded by CTCF
(Figure S3H). In this case, a peak height threshold of 50 would
identify 58% of regulated promoters, but also 24%–29% of
nonregulated promoters and 19% of intergenic regions. There-
fore, although there is a trend toward higher peaks near regu-
lated genes, peak height is neither a sensitive nor specific
discriminator of function.
MyoD Binding in Primary Muscle Cells and Fibroblasts
Expressing MyoD
To determine whether our findings in the C2C12 myoblast cell
line are representative of primary muscle cells, we performed
similar ChIP-seq on myoblasts isolated from the leg muscles of
an adult mouse and differentiated to myotubes in vitro. In addi-668 Developmental Cell 18, 662–674, April 20, 2010 ª2010 Elsevier Ition, because expression of MyoD converts MEFs to skeletal
muscle, we also performed ChIP-seq for MyoD binding in
MEFs transduced with a retrovirus expressing MyoD (MyoD-
MEFs) at levels comparable to C2C12 cells. Each sample had
a similar number of mappable reads, and using a 12-read cutoff
that identifies 25,956 peaks in C2C12 myotubes, we found that
the primary myotubes have 39,075 binding regions and that
the MyoD-MEFs have 23,286 MyoD-binding regions. The three
binding profiles (C2C12 myotubes, primary myotubes, and
MyoD-MEFs) showed a high degree of similarity, with a Pearson
correlation coefficient of 0.75 between C2C12 myotubes and
MyoD-MEFs, 0.67 between C2C12 myotubes and primary myo-
tubes, and 0.63 between MyoD-MEFs and primary myotubes
(Figure S4A). Among the peaks with 12 or more reads in
C2C12 myotubes, 93% and 90% have at least 6 reads in the
same regions in MyoD-MEFs and in primary myotubes, respec-
tively (Figure 4A), which increase to 96% and 97% when only
considering peaks that increase with differentiation (Figure 4B).
Similarly, 73% and 82% of the peaks in primary myotubes
have at least six reads in the same regions in C2C12 myotubesnc.
Figure 4. MyoD Binding in Primary Myo-
tubes and Fibroblasts
(A) The MyoD-binding regions are largely shared
between C2C12 myotubes (open circle) and pri-
mary myotubes (cross), or mouse embryonic
fibroblasts expressing MyoD (open triangle). To
assess the concordance between C2C12 myo-
tubes and the other two types of myotubes,
MyoD-bound regions in C2C12 myotubes with at
least 12 coverage were treated as reference, and
the proportion of peaks that were also present in
primary myotubes or fibroblasts expressing MyoD
at each given cutoff was plotted.
(B) The plot is similar to that in (A), except that the
analysis was restricted to the peaks present in
C2C12 myotubes that increased in coverage
during differentiation, indicating a high similarity
in this set of peaks that are associated with differ-
entially expressed genes (see [A]).
(C)–(F) show the MyoD-binding profiles at the
Acta1, Tnnc2, Actc1 and Mef2a loci.
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a larger number of peaks in primary myotubes. Examination of
several MyoD-regulated genes also showed that the MyoD-
binding regions in the three different types of muscle cells
were very similar, although some binding regions varied among
the muscle cell types (Figures 4C–4F). Therefore, the MyoD-
binding regions are extremely similar in C2C12 cells, primary
muscle cells, and MEFs transduced with MyoD.
Functional Assessment of Genome-wide MyoD Binding
To determinewhether all identifiedMyoD-binding sites represent
classic enhancer elements, we selected 25 isolated peaks
covering conserved regions that increased, decreased, or did
not change peak height with differentiation, and cloned regions
(ranging from 204 to 567 nt under the center of the peak that
maximized the inclusion of evolutionarily conserved sequences)
into a reporter construct that contains the SV40 promoter driving
luciferase (pGL3 promoter), and enhancer activity wasmeasured
in C2C12 myoblasts and myotubes. Although some regions
showed enhancer activity in this assay (5 of 11 intragenic regions
and 5 of 14 intergenic regions), the majority of MyoD-bindingDevelopmental Cell 18, 662–regions did not show standard enhancer
activity (Figures S4B and S4C).
To determine whether the genome-
wide binding of MyoD might alter regional
chromatin structure, we assessed histone
H3 lysine 4 trimethylation (H3K4me3) and
histone H4 acetylation (H4Ac), a marker of
active promoters and a modification
broadly associated with active chromatin
at both enhancers and promoters (Heintz-
man et al., 2007). We performedChIP-seq
for these modifications in MEFs without
MyoD and MyoD-MEFs differentiated to
skeletal muscle, permitting us to compare
the same genomic region with or without
MyoD binding. We used a 500 nt slidingwindow across the genome to identify regional changes in
histone modifications between MEFs and MyoD-MEFs, and we
plotted the degree of change against the number of MyoD reads
in the MyoD-MEFs. There was very little increase in H3K4me3 at
MyoD-bound regions genome wide (Figure 5A), consistent with
the expression array data indicating that MyoD regulates the
transcription of 4% of the tiled genes and the fact that most
of the binding sites are not in the promoter regions that are
histone H3 lysine 4 trimethylated in actively transcribed genes.
In contrast, there was a substantial increase in H4Ac at regions
bound byMyoD (Figure 5B). Thiswas not secondary to a nonspe-
cific increase in histone acetylation because regions not bound
by MyoD did not show a shift to increased acetylation (left
most part of Figure 5B), nor did regions bound by another
DNA-binding factor, CTCF, show increased levels of either
H3K4me3 or H4Ac in the MyoD-MEFs (Figures S5A and S5B).
To determine whether the MyoD-associated H4Ac changes
occurred at intergenic regions as well as gene-associated
regions, we plotted the change in H4Ac reads in a 500 nt
window centered on the location of MyoD peaks, at all sites
in the genome, only at intergenic sites (defined as more than674, April 20, 2010 ª2010 Elsevier Inc. 669
Figure 5. MyoD Induces Histone H4 Acety-
lation at Binding Sites Genome Wide
(A) The expression of MyoD does not induce
changes in H3K4me3 at the majority of bind-
ing sites genome wide. The difference of total
H3K4me3 reads between MyoD-MEFs and
MEFs in a 500 nt sliding window (y axis) was
plotted against the square root of maximal MyoD
peak height (x axis) within the same sliding window
across the genome. See Experimental Procedures
for details.
(B) Expression of MyoD induces H4Ac at binding
sites genome wide. The plot is similar to that in
(A), except that the y axis is the H4Ac differences.
(C) The expression of MyoD increases H4Ac in
MyoD-bound regions. For each MyoD-bound
peak, the difference of total H4Ac reads between
MyoD-MEFs and MEFs in a 500 nt window
centered at the peak summit (y axis) was plotted
against the square root of maximal MyoD peak
height (x axis).
(D) Similar to (C), except that only the intergenic
MyoD-binding peaks are considered.
(E) C2 myoblasts and myotubes have increased
H4Ac at MyoD-binding sites. Quantitative real-
time PCRs were performed at 20 loci on H4Ac
ChIP samples from C2C12 myoblasts and myo-
tubes. The Hbb promoter region was used as a
baseline control. The fold enrichments were
calculated relative to the amount of input chro-
matin. The error bars indicate the difference
between the duplicate measurements for the
particular experiments. Hbb, Hemoglobin-beta;
AMY2, Amylase 2; A1–A12, intergenic regions;
B1–B4, promoter regions; C1–C4, intron regions.
See Table S1 for ChIP-seq and qPCR measure-
ment of MyoD binding at these regions.
Developmental Cell
MyoD Binds Genome Wide10 kb from an annotated gene), or at MyoD-binding sites in
the MyoD-MEFs that intersect with intergenic constitutively
bound sites in C2C12 myoblasts and myotubes. MyoD bind-
ing at regions throughout the genome was associated with
increased H4Ac (Figures 5C and 5D), including the intergenic
binding sites corresponding to unchanged peaks in C2C12 cells
(Figure S5C).
Finally, we performed H4Ac ChIP and locus-specific real-time
qPCR to assess acetylation at a set of MyoD-binding sites
in C2C12 myoblasts and myotubes. When compared to the
promoter of the inactive hemoglobin-beta (Hbb) gene, the inter-
genic MyoD-binding regions showed a 4- to 105-fold enrichment
of H4Ac (Figure 5E, regions A1–A12). Similar enrichments were
seen at binding sites in promoter regions (regions B1–B4) and
introns (regions C1–C4). For most of the sampled regions, the
MyoD peak height was approximately the same in myoblasts
and myotubes (see Table S1A), and the H4Ac enrichment was
similar in myoblasts and myotubes. At the two regions where
MyoD binding substantially increased with differentiation (B3 and670 Developmental Cell 18, 662–674, April 20, 2010 ª2010 Elsevier Inc.C2), the degree of H4Ac also increased
substantially with differentiation. The
degree of H4Ac enrichment at the MyoD-
binding sites compared favorably to the
enrichment at the promoter of the constitu-tively expressed Timm17b gene, which ranged from 8- to 14-fold.
Therefore, the genome-widebindingofMyoD inC2C12myoblasts
andmyotubes is associatedwith regional histone acetylation, indi-
catingagenome-wide role forMyoD inbroadly reprogramming the
epigenetic state of the specified myoblast.
DISCUSSION
Our study identifies60,000MyoD-binding sites in nonrepetitive
regions of autosomal chromosomes. Including the sex chromo-
somes would modestly increase the number of sites, whereas
including binding to repetitive regions could substantially
increase the number and distribution of MyoD-binding sites in
the genome. Using our very conservative requirement for 12
overlapping reads to identify a MyoD-binding site, somewhere
between 41% and 74% of genes are associated with a MyoD-
binding region, and it is likely that with looser stringency, and
including repetitive elements, these already high percentages
would be further increased.
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binding (i.e., sites that are preferentially bound in myoblasts or
differentiated myotubes) and gene expression. This suggests
that sites regulating gene transcription in myotubes require addi-
tional factors to modulate MyoD binding. Indeed, the sites asso-
ciated with myotube-expressed genes are enriched for motifs of
factors that are activated by MyoD and function with MyoD in
a positive feed-forward circuit, as demonstrated previously
withMef2 (Penn et al., 2004) andMyog (Cao et al., 2006). In addi-
tion, the Pbx/Meis complex cooperates with MyoD in activating
a subset of genes (Berkes et al., 2004; Maves et al., 2007).
Another finding was that genes decreasing expression with
differentiation were associated with decreased MyoD binding
at sites enriched for RP58 and AP1 motifs. A recent study (pub-
lished after our analysis was complete) identified RP58 as a gene
activated byMyoD duringmuscle differentiation that suppresses
Id2 and Id3 transcription (Yokoyama et al., 2009), and our
expression array time course data show that RP58 is upregu-
lated at 24 and 48 hr of differentiation in C2C12 cells (data not
shown). The RP58-binding sites that repress the Id genes over-
lapwithMyoD-binding sites in peaks that decrease with differen-
tiation. Therefore, this strongly suggests that MyoD positively
regulates Id expression in the myoblast and then, during differ-
entiation, activates RP58, and that RP58 suppresses MyoD
binding through a negative feed-forward mechanism, an inco-
herent feed-forward loop that can provide fold-change detection
(Goentoro et al., 2009). This would be consistent with our
previous observation that Id RNAs are transiently induced
when MyoD is expressed in MEFs (Bergstrom et al., 2002).
Because we identified RP58 as being associated with differenti-
ation-decreased MyoD peaks through a de novo motif search, it
is likely that many other genes in addition to the Ids are similarly
regulated.
Another interesting finding of our study is that the majority of
sites are constitutively bound by MyoD in both myoblasts
and myotubes. In general, these sites are not associated with
MyoD-mediated changes in regional gene expression, based
on expression arrays, regional H3K4me3, and preliminary
studies on induced RNAs (Y. Cao, unpublished data). Studies
of transcription factor binding in Drosophila also show binding
at thousands of sites in the genome in addition to binding at
regulated genes (Li et al., 2008; MacArthur et al., 2009). In this
case, higher-affinity binding occurred at regulated genes, and
lower-affinity binding occurred in regions not regulated by the
factors, suggesting that the low-affinity genome-wide binding
might be ‘‘nonfunctional’’ in regard to direct transcriptional acti-
vation. In our study, peak height as ameasure of affinity does not
accurately discriminate between sites associated with transcrip-
tionally regulated or nonregulated genes, and, although peaks at
regulated genes trend higher than intergenic peaks, the same is
true when comparing peaks at nonregulated genes to intergenic
peaks. Furthermore, our demonstration that MyoD binding
induces regional histone acetylation at sites throughout the
genome, presumably through direct recruitment of histone ace-
tyltransferases (Puri et al., 1997), indicates that MyoD binding
has a functional consequence at these sites that is independent
of regional regulation of transcription. The fact that the MyoD-
recruited acetylation occurs at constitutively bound sites in
myoblasts indicates a role for MyoD in broadly modifying theDevechromatin structure of myoblasts. Future studies will be neces-
sary to determine the biological function, if any, of these epige-
netic changes in the specification of the myoblast lineage.
Our study is in general agreement with, and significantly
extends, the previous profiling of global MyoD-binding sites
that used ChIP-chip technology (Blais et al., 2005; Cao et al.,
2006). First, in the subset of promoter regions that can be directly
compared between the studies, we identify MyoD binding in
almost all of the promoter regions identified as bound in both
studies (Figure S3B; data not shown). Second, the prior ChIP-
chip studies only surveyed the promoter regions of annotated
genes, whereas the ChIP-seq technology allowed us to survey
the entire genome. In fact, our study showed that 24% of
the MyoD peaks are located in the promoter-proximal regions
(±2 kb from a TSS). This might be significant because a recent
study has shown that the chromatin state at promoters is largely
shared by different tissues, whereas tissue-specific gene
expression is highly correlated with the chromatin state of the
enhancers located outside of the promoter region (Heintzman
et al., 2009). Therefore, many of the functional MyoD-binding
sites might be outside of the promoter regions. Consistent with
this hypothesis, although 24% of the peaks are located within
the promoter-proximal regions, only 10% of the differentially
bound peaks are in these promoter regions.
The consensus E-box motif is present in 96% of the MyoD-
binding regions, and, as predicted from previous in vitro degen-
erate binding site selections, there is a preference for E-boxes
with internal CC or GC sequences, with 89% of MyoD-binding
regions containing either CACCTG or CAGCTG sites. In vitro
selection studies suggest that CACCTG is preferred by MyoD:
E-protein heterodimers and that CAGCTG is preferred by
MyoD homodimers (Blackwell and Weintraub, 1990); however,
homo- and heterodimers can bind to either sequence. Prior
studies suggested that the expression of Id proteins in myo-
blasts competed with MyoD for E-protein dimerization and
limited the formation of MyoD:E-protein heterodimers (Benezra
et al., 1990; Jen et al., 1992). In this regard, we have not distin-
guished heterodimer binding from homodimer binding in our
study, but we do note that, although there is an enrichment of
the consensus heterodimer motif in peaks that increase with
differentiation (data not shown), the E-box sequence does not
accurately discriminate between constitutively bound sites
and myotube-specific sites. Therefore, if there is a shift between
homodimer binding and heterodimer binding during differentia-
tion, it is not obviously represented in the sequence of the bound
E-box.
In summary, our findings add an interesting and challenging
element to the consensus model for how myogenic bHLH tran-
scription factors regulate myogenesis. Similar to the consensus
model (Berkes and Tapscott, 2005), we find regulated binding at
many genes activated by MyoD during myogenic differentiation
and the association with motifs for Mef2 and other factors,
consistent with prior ChIP-chip studies (Blais et al., 2005) and
with a feed-forward temporal regulation of gene expression
(Penn et al., 2004). The major finding not anticipated by the
consensus model is the genome-wide MyoD binding associated
with histone acetylation in both myoblasts and myotubes.
Dynamic changes in nuclear organization are necessary for
genes to be repositioned during differentiation (Hu et al., 2008;lopmental Cell 18, 662–674, April 20, 2010 ª2010 Elsevier Inc. 671
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et al., 2010), and progenitor cell commitment requires a transition
between two different ordered nuclear states (Rajapakse et al.,
2009). Although speculative, the genome-wide binding of
MyoD and associated histone acetylation might initiate new
patterns of gene looping and chromosome architecture neces-
sary for the transition between nuclear states.
EXPERIMENTAL PROCEDURES
Cell Culture
C2C12 cells were grown in DMEM with 10% fetal bovine serum (Hyclone),
and differentiation was induced at confluence in DMEM with 2% horse
serum, 10 mg/ml insulin, and 10 mg/ml transferrin (differentiation media, DM)
for 48 hr. Mouse embryo Myf-5/MyoD-null fibroblasts transduced with
pCLBABE-Myod retrovirus or control pCLBABE retrovirus were maintained in
DMEM with 2 mg/ml puromycin and 10% bovine calf serum (Hyclone), and
differentiation was induced at confluence in DM. Primary mouse myoblasts
were isolated from adult mouse hindlimb muscle (see Supplemental Experi-
mental Procedures for details) and were cultured in Ham’s F10 media supple-
mented with 20% FBS, 2.5 ng/ml bFGF, penicillin/streptomycin, and L-gluta-
mine. Cells were differentiated for 3 days in DM before collection.
Chromatin Immunoprecipitation and Ultra-High-Throughput
Sequencing
ChIP was performed as previously described (Bergstrom et al., 2002), with the
exception that sonication was performed to generate final DNA fragments of
150–600 bp. The three anti-MyoD polyclonal antibodies were previously
characterized (Tapscott et al., 1988). ChIP DNA samples were prepared for
sequencing according to the manufacture’s recommended protocol, with
two modifications: (1) DNA fragments ranging from 150 to 300 bp were
selected at the gel-selection step; (2) 21 cycles of PCR were performed at
the PCR amplification step instead of 18. The samples were sequenced with
the Illumina Genome Analyzer II.
Defining Peaks
We extracted the sequences by using the Firecrest and Bustard programs
from package GApipeline-0.3.0, and we used MAQ (version 0.6.6) to align
reads to the mouse reference genome (NCBI v37, mm9). We allowed up to
two mismatches in the first 28 bp seed regions. We discarded reads with
a MAQ score less than 15, which eliminates most reads mapping to multiple
loci in the reference genome. Tominimize artifacts of PCR amplification during
sample preparation, we retained only one copy of any duplicated sequence.
Preliminary analysis showed strong agreement among data from the three
antisera. Therefore, for the same sample condition, we combined reads from
all three antisera in our study. For the purpose of identifying peaks, we
extended each read to a total of 200 bp in the sequencing orientation. We
calculated coverage for each genomic position as the number of (extended)
reads that overlap with the position. To identify a reasonable coverage cutoff,
we considered the distribution of the maximum coverage depth within an
island (defined as a contiguous region of coverage one or more). We assumed
a Poisson-null distribution (reads sampled uniformly from the genome) and
estimated the Poisson parameters based on the number of islands with
a coverage of one and two. Given this, we estimated the false discovery rate
(FDR) at any given cutoff by the ratio of the expected and observed number
of islands at that cutoff. Simulation studies suggest that the estimated false
discovery rates are relatively conservative. Data from the preimmune control
sample fits the Poisson distribution well in general, except for a few high peaks
that were present in all samples. We consequently removed any peaks whose
coverage was within 4-fold of the control sample coverage. Based on this
Poisson analysis, peak cutoffs of 6 and 12 provide FDRs of 0.012 and
107, respectively. We used the very stringent threshold of 12 to define peaks
for further analysis. For each peak, we define the peak summit to be the loca-
tion with maximum coverage. We used the 200 bp regions centered at the
peak summits for sequence/motif analysis (see below), and we used the
midpoint of the peak summits to calculate the distance from peaks to other
genomic locations, e.g., gene transcription start sites (TSSs).672 Developmental Cell 18, 662–674, April 20, 2010 ª2010 Elsevier IControl Data Selection
To evaluate the sequence signal of myotube peaks, we created a control data
set to serve as a comparison. We selected a set of singleton reads with a size
equal to the number of myotube peaks. This data set was chosen so that it also
shares the same distribution of distance to TSSs and has similar distribution
among genes, introns, exons, and intergenic regions as the myotube peaks.
This control data set effectively adjusts for the TSS bias in the myotube peaks,
as well as the potential sequencing alignment bias, so that comparisons of
myotube peaks and the control are not affected by these two factors.
Gene Context Analysis
We collected gene annotation from the UCSC browser (mm9, July 2007)
known gene track. We first identified the peaks within the promoter regions
(±500 bp from a TSS). We then assigned the remaining peaks to the 30 end
(±500 bp from the 30 end of the transcripts); exon; intron; and upstream
(500 to 10 kb of TSSs), downstream (+500 to +10 kb from the 30 end of
the transcripts), and intergenic regions (with a distance greater than 10 kb
from any transcript). Promoter-proximal regions were defined as regions
within ±2 kb of a TSS. Therefore, each peak may be assigned to multiple
categories, except those within the promoters.
Association of MyoD-Binding Sites to Genes
We associated a peak to its closest TSS within the region flanked by CTCF-
binding sites, which were identified in a ChIP-seq experiment on mouse
embryonic stem cells (GEO accession number GSM288351). The original
CTCF peaks were translated from mm8 to mm9 with the UCSC Liftover tool.
Detection of Differential Peaks
To compare two ChIP-seq samples, we combine them, treating the combined
data as if it were from a single sample, then call peaks as described above.
Although this may favor false positives, wewant to find all peaks and are willing
to accommodate a small number of additional regions that are not peaks, but
have some hallmarks of a peak. For each of the potential peak regions, we
obtain the number of reads in one sample (xi) and in the other (yi), and we
then fit them to the regression model f(yi) f(xi), where f is an appropriate
log-scale transformation. The intercept in the regression model may be inter-
preted as an adjustment for unequal sample sizes (number of reads); more
data equate to a scale factor in the xi or yi values, which translates to an addi-
tive shift on the log scale.
We used this approach to compare myotube to myoblast by using the vari-
ance stabilization and normalization transformation (VSN) (Huber et al., 2002).
VSN is essentially at log scale, and we mainly care about the intercept. For
robustness, we used the median of di = f(yi)  f(xi) as an estimate of the inter-
cept, and the median absolute deviation (mad) of di as an estimate of standard
deviation. The residuals are calculated as (di  med(di))/mad(di). A peak is
considered to be differentially bound if the absolute value of the residual is
greater than 1.64, which corresponds to a 95% confidence interval if the resid-
uals follow a normal distribution.
Our approach has several advantages. First, peak calling in the combined
samples, as opposed to each sample separately, avoids comparing peaks
with different boundaries in the two samples. The regression approach is also
appealing because it frames the problem in the familiar context of classical
statistics, where a series of observations aremadeon a number of experimental
units. In the ChIP-seq scenario, the experimental units are peaks as defined
above, and observations associated with each peak include the number of
reads overlapping that peak. The analogy is less than perfect because the
experimental units, in this case (peaks), are determined from the data itself.
However, we do not expect this to be problematic, as peaks corresponding to
strong binding sites would usually be identified correctly, and those with weak
signal in both samples would either be unidentified or deemed not significantly
different. The regression approach is evenmore appealing in situations inwhich
the experimental units are independently defined, such as promoter regions, or
computationally predicted transcription factor-binding sites. Additionally, it
admits inclusion of other covariates such as local GC content, if desired.
Motif Analysis
We have developed a discriminative motif discovery tool especially designed
for ChIP-Seq application. We formulate the motif search problem innc.
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contains putative transcription factor-binding sites (e.g., regions under peaks),
and a negative set that provides appropriate background (e.g., the control data
set above). The goal is to find a motif whose occurrences best discriminate
between the positive and negative data sets. Unlike other motif search
methods that model a motif by a position weight matrix (PWM) or a consensus
pattern using IUPAC codes, we define a motif simply as a collection of oligo-
nucleotides. (Note that the motif logos presented in the figures are visual
summaries of the mono- and dinucleotide frequencies of the oligos in these
collections, not the collections themselves.) This ‘‘collection of oligos’’ repre-
sentation of motifs is very flexible and is capable of describing arbitrary depen-
dencies among different positions in motifs, which cannot be captured by
traditional motif models. The main drawback of this model is the large search
space. To address this problem, we used a greedy algorithm to navigate the
search space, and we tested for statistical significance at every step to avoid
overfitting. With our large ChIP-seq training sets, this approach enables us to
capture subtle but statistically significant signals. The regression framework
also enables us to add additional regression terms to counter possible biases
the in positive or negative data sets, such as GC content. For given length n,
the method first enumerates all n-mers, and then uses the frequencies of
each n-mer to fit a logistic regression model, where the response specifies
whether a sample is from the positive or the negative set. Themost statistically
significant n-mer is chosen as the seed for the topmotif. We then try all variants
of the seed within a given Hamming distance (1 or 2), and add them to themotif
if the combined motif frequencies fit the regression model better. After
exhausting all of the variants, we extend the motif one position at a time, trying
all four choices, A, C, G, and T, and exclude each extended pattern iteratively
if the remaining set is more statistically significant. After refining the top motif,
we mask all of its occurrences in the sequence data set, and we repeat the
whole process to find the next motif. The ranks for patterns that overlap with
previous motifs tend to drop significantly after masking, which prevents
reporting redundant motifs. We used this method in several contexts. For
example, to discover motifs that associate with myotube peaks, we selected
the 200 bases centered at the summit of each myotube peak versus the
200 bases of each extended read in the control data set described above.
Similarly, in the myoblast/myotube comparison, we used this method to
discover motifs that discriminate between peaks that increase (and, sepa-
rately, decrease) upon differentiation into myotubes versus those that are
present in both but remain unchanged in height. In both comparisons, the posi-
tive sets were selected from peaks determined to be differentially increased
(decreased, resp.) as described above, and the negative set was comprised
of unchanged peaks outside CpG islands with absolute differential residuals
less than 0.2.
GO Analysis
Gene set enrichment analysis (GSEA) was performed using the Bioconductor
GOstats package (Falcon and Gentleman, 2007; Gentleman et al., 2004). This
method computes hypergeometric p values for over- or underrepresentation
of each GO term in the specified ontology for the gene set of interest. Each
gene is represented by a unique Entrez ID, and genes with no Entrez ID
were not included in this analysis. The annotation of genes is based on the
Bioconductor annotation package org.Mm.eg.db.
TRANSFAC Analysis
Conserved transcription factor-binding sites were collected from the UCSC
browser (contributed by TRANSFAC) for the human genome (hg18). We
successfully lifted 98% of sites to the mouse genome (mm9). The frequency
of each conserved TRANSFAC-binding site in the myotube peaks (200 bp
centered on the summits) and the control regions were counted.
Detection of Differential Histone Modification State
To evaluate global H4Ac changes, we scanned the entire genome with a
500 bp sliding window with 250 bp overlap. In each window, we counted the
number of overlapping H4Ac reads in MEFs expressing MyoD and MEF
control. We took the square root of the number of H4Ac reads in each sample
and fit a local regression curve on the difference of the two versus the mean, to
adjust for any potential bias due to the relative abundance of H4Ac in the two
samples. The residual is defined as the difference after subtraction of this localDevecorrection divided by the standard deviation. Similar analysis was performed
on H3K4me and was associated with the MyoD/CTCF binding.
Microarray Analysis
Triplicate total RNA samples were collected from 50% confluent proliferating
C2C12 cells, 95% confluent C2C12 cells, and C2C12 cells differentiated for
2 days. Samples were analyzed by Illumina Mouse Whole Genome arrays.
Probe intensities were corrected, normalized, and summarized by the Lumi
package of Bioconductor (Du et al., 2008). Differentially expressed genes
were identified by the LIMMA package of Bioconductor (Smyth, 2004).
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